Juyi Li

2.0k total citations
47 papers, 1.1k citations indexed

About

Juyi Li is a scholar working on Molecular Biology, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, Juyi Li has authored 47 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 12 papers in Surgery and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Juyi Li's work include Liver Disease Diagnosis and Treatment (7 papers), Genetic factors in colorectal cancer (6 papers) and COVID-19 Clinical Research Studies (5 papers). Juyi Li is often cited by papers focused on Liver Disease Diagnosis and Treatment (7 papers), Genetic factors in colorectal cancer (6 papers) and COVID-19 Clinical Research Studies (5 papers). Juyi Li collaborates with scholars based in China, United Kingdom and United States. Juyi Li's co-authors include Aiping Deng, Hongmei Zhang, Xiufang Wang, Jian Chen, Jian Chen, Xiufang Wang, Zhongjing Wang, Xiong Jia, Xiangli Bai and Si Jin and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Diabetes Care and Scientific Reports.

In The Last Decade

Juyi Li

44 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Juyi Li China 13 683 367 199 181 130 47 1.1k
Hongmei Zhang China 12 772 1.1× 421 1.1× 204 1.0× 148 0.8× 160 1.2× 45 1.3k
Pamir Atagündüz Türkiye 22 582 0.9× 284 0.8× 79 0.4× 65 0.4× 331 2.5× 64 1.7k
Yanmei Huang China 16 212 0.3× 131 0.4× 80 0.4× 165 0.9× 167 1.3× 45 994
Minhui Dai China 21 284 0.4× 119 0.3× 83 0.4× 97 0.5× 625 4.8× 47 1.6k
Yufei Xiang China 16 415 0.6× 260 0.7× 723 3.6× 623 3.4× 181 1.4× 30 1.4k
Guyi Wang China 15 399 0.6× 167 0.5× 29 0.1× 89 0.5× 119 0.9× 32 732
Veronica Resi Italy 16 222 0.3× 88 0.2× 60 0.3× 398 2.2× 126 1.0× 41 969
Edison Jahaj Greece 17 338 0.5× 165 0.4× 31 0.2× 103 0.6× 130 1.0× 73 735
Shaghayegh Khanmohammadi Iran 12 239 0.3× 125 0.3× 27 0.1× 93 0.5× 149 1.1× 37 766

Countries citing papers authored by Juyi Li

Since Specialization
Citations

This map shows the geographic impact of Juyi Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juyi Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juyi Li more than expected).

Fields of papers citing papers by Juyi Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juyi Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juyi Li. The network helps show where Juyi Li may publish in the future.

Co-authorship network of co-authors of Juyi Li

This figure shows the co-authorship network connecting the top 25 collaborators of Juyi Li. A scholar is included among the top collaborators of Juyi Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juyi Li. Juyi Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
3.
Li, Juyi, et al.. (2024). A real-world pharmacovigilance analysis for agalsidase beta: findings from the FDA adverse event reporting database. Expert Opinion on Drug Safety. 25(3). 561–572. 1 indexed citations
4.
Yuan, Jie, Shuai Liu, Xue Meng, et al.. (2024). Investigating causal associations among gut microbiota, metabolites and autoimmune hypothyroidism: a univariable and multivariable Mendelian randomization study. Frontiers in Immunology. 14. 1213159–1213159. 9 indexed citations
5.
Wang, Xiufang, Junhui Yang, Aiping Deng, et al.. (2024). Toxic Epidermal Necrolysis Observed in a Patient With the HLA-B*1502 Treated With Levofloxacin. Clinical Therapeutics. 46(12). 1082–1085. 1 indexed citations
6.
Li, Juyi, Yang Ge, Yuwei Chai, et al.. (2024). THSR Mediated MiR374b Targeting C/EBP β/FOXO1 to Accelerate Thyroid Stimulating Hormone-Induced Hepatic Steatosis. PubMed. Volume 16. 91–104. 1 indexed citations
7.
Li, Juyi, et al.. (2024). GBA3 promotes fatty acid oxidation and alleviates non-alcoholic fatty liver by increasing CPT2 transcription. Aging. 16(5). 4591–4608. 3 indexed citations
8.
Li, Juyi, Xiaofang Liang, Xiufang Wang, et al.. (2023). A missense GDF5 variant causes brachydactyly type A1 and multiple‐synostoses syndrome 2. JOR Spine. 7(1). e1302–e1302.
9.
Cheng, Wenzhuo, Weihua Wang, Aiping Deng, et al.. (2023). Identification of an LDLR variant in a Chinese familial hypercholesterolemia and its relation to ROS/NLRP3-Mediated pyroptosis in hepatic cells. Journal of Geriatric Cardiology. 20(5). 341–349. 2 indexed citations
10.
Li, Juyi, Chengzhi He, Jing Gong, et al.. (2023). Identification of a novel CNV at the APC gene in a Chinese family with familial adenomatous polyposis. Frontiers in Molecular Biosciences. 10. 1234296–1234296. 1 indexed citations
11.
Li, Juyi, et al.. (2023). Identification and Validation of Hub Immune-Related Genes in Non-Alcoholic Fatty Liver Disease. International Journal of General Medicine. Volume 16. 2609–2621. 1 indexed citations
12.
Li, Juyi, Xiufang Wang, Huihui Mao, et al.. (2022). Precision therapy for three Chinese families with maturity-onset diabetes of the young (MODY12). Frontiers in Endocrinology. 13. 858096–858096. 9 indexed citations
13.
Zhou, Jun, Juyi Li, Yan Zhao, et al.. (2022). Aqueous extract of Scrophularia ningpoensis improves insulin sensitivity through AMPK-mediated inhibition of the NLRP3 inflammasome. Phytomedicine. 104. 154308–154308. 7 indexed citations
14.
Zhang, Yuanyuan, et al.. (2022). Correlation between the thyroid hormone levels and nonalcoholic fatty liver disease in type 2 diabetic patients with normal thyroid function. BMC Endocrine Disorders. 22(1). 144–144. 8 indexed citations
15.
Li, Juyi, Xiufang Wang, Aiping Deng, et al.. (2021). Precision Therapy for a Chinese Family With Maturity-Onset Diabetes of the Young. Frontiers in Endocrinology. 12. 700342–700342. 1 indexed citations
16.
Zhu, Lin, Xiaoyan Yang, Juyi Li, et al.. (2021). Leptin gene-targeted editing in ob/ob mouse adipose tissue based on the CRISPR/Cas9 system. Journal of genetics and genomics. 48(2). 134–146. 15 indexed citations
17.
Li, Juyi, et al.. (2021). Two novel and one known pathogenic germline mutations in MMRs in Chinese families with Lynch syndrome. Genes & Diseases. 9(2). 292–295. 1 indexed citations
18.
Zhang, Yuanyuan, et al.. (2021). Correlational study on the levels of 25-hydroxyvitamin D and non-alcoholic fatty liver disease in type 2 diabetic patients. BMC Endocrine Disorders. 21(1). 100–100. 8 indexed citations
19.
Li, Juyi, et al.. (2020). A Missense Mutation in IRS1 is Associated with the Development of Early-Onset Type 2 Diabetes. International Journal of Endocrinology. 2020. 1–8. 9 indexed citations
20.
Li, Juyi, et al.. (2014). Establishment and Optimization of Two-dimensional Electrophoresis Technique in Hydatid Fluid Proteome of Echinococcus granulosus. Pakistan Journal of Zoology. 46(5). 1249–1254. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026